These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 37880682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Identification of a dysregulated CircRNA-associated gene signature for predicting prognosis, immune landscape, and drug candidates in bladder cancer.
    Shen C, Li Z, Zhang Y, Zhang Z, Wu Z, Da L, Yang S, Wang Z, Zhang Y, Qie Y, Zhao G, Lin Y, Huang S, Zhou M, Hu H.
    Front Oncol; 2022; 12():1018285. PubMed ID: 36300085
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
    Shen C, Yan Y, Yang S, Wang Z, Wu Z, Li Z, Zhang Z, Lin Y, Li P, Hu H.
    Funct Integr Genomics; 2023 Jan 23; 23(1):46. PubMed ID: 36689018
    [Abstract] [Full Text] [Related]

  • 6. Construction and Validation of a Prognostic Model Based on Pyroptosis-related Genes in Bladder Cancer.
    Shen C, Han C, Li Z, Yan Y, Li C, Chen H, Fan Z, Hu H.
    Comb Chem High Throughput Screen; 2024 Jan 23; 27(16):2335-2349. PubMed ID: 37849225
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y, Sun X, Liu G, Li H, Yu M, Zhu Y.
    Front Immunol; 2023 Jan 23; 14():1301157. PubMed ID: 38299148
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comprehensive FGFR3 alteration-related transcriptomic characterization is involved in immune infiltration and correlated with prognosis and immunotherapy response of bladder cancer.
    Xu T, Xu W, Zheng Y, Li X, Cai H, Xu Z, Zou Q, Yu B.
    Front Immunol; 2022 Jan 23; 13():931906. PubMed ID: 35958598
    [Abstract] [Full Text] [Related]

  • 12. Metabolic-associated signature and hub genes associated with immune microenvironment and prognosis in bladder cancer.
    Guo Y, Zheng Z, Mao S, Yang F, Wang R, Wang H, Liu J, Li C, Wang Q, Zhang W, Yao X, Liu S.
    Mol Carcinog; 2023 Feb 23; 62(2):185-199. PubMed ID: 36250643
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prognostic Signature Development on the Basis of Macrophage Phagocytosis-Mediated Oxidative Phosphorylation in Bladder Cancer.
    Qu G, Xu Y, Lu Z, Nie H, Tang C, Hou J, Wen X.
    Oxid Med Cell Longev; 2022 Feb 23; 2022():4754935. PubMed ID: 36211821
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
    Sun X, Xin S, Jin L, Zhang Y, Ye L.
    Bioengineered; 2022 May 23; 13(5):13986-13999. PubMed ID: 35758021
    [Abstract] [Full Text] [Related]

  • 18. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C, Fu C, Suo Y, Li K, Zhang Z, Yang S, Zhang Y, Lin Y, Li Z, Wu Z, Huang S, Chen H, Fan Z, Hu H.
    Heliyon; 2023 Jun 23; 9(6):e16897. PubMed ID: 37346342
    [Abstract] [Full Text] [Related]

  • 19. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.
    Chen H, Yang W, Li Y, Ma L, Ji Z.
    Front Immunol; 2023 Jun 23; 14():1198878. PubMed ID: 37325625
    [Abstract] [Full Text] [Related]

  • 20. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C, Liu D, Wang F, Liu Y, Xie J, Xie J, Xie Y.
    Front Immunol; 2022 Jun 23; 13():1038927. PubMed ID: 36451813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.